3558 POSTER Metastatic small bowel adenocarcinoma: favourable outcome in patients with primary tumour resected – retrospective analysis of 44 cases

Albrecht Kretzschmar(Roche (Switzerland)), Jakob Hartmann(Harvard University), Daniel Pink(Universitätsmedizin Greifswald), Ralf‐Dieter Hofheinz(University of Mannheim), Ines Meisinger, M. Stahl(Kliniken Essen-Mitte), P. Thuss-Patience, Gunnar Folprecht

European Journal of Cancer Supplements

September 1, 2007

10.1016/s1359-6349(07)71061-3

Cited by 0

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

|New England Journal of Medicine|2015|1.7k

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

|The Lancet Oncology|2009|960

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

|Journal of Clinical Oncology|2008|784

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738